Baader Bank Aktiengesellschaft Makes New Investment in DexCom, Inc. $DXCM

Key Points

• Baader Bank Aktiengesellschaft invested approximately $393,000 in DexCom, acquiring 4,500 shares of the medical device company's stock during the 2nd quarter.
• Insider trading activity has been noted, with EVP Michael Jon Brown selling 500 shares and Director Mark G. Foletta selling 2,750 shares on August 15th.
• DexCom's stock recently saw a 11.0% decline, with the current consensus rating on the stock being a "Moderate Buy" and a target price of $99.89.

Baader Bank Aktiengesellschaft bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 4,500 shares of the medical device company's stock, valued at approximately $393,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of DXCM. Brighton Jones LLC lifted its holdings in shares of DexCom by 257.7% during the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares during the period. Bank Pictet & Cie Europe AG lifted its holdings in shares of DexCom by 1.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after purchasing an additional 2,010 shares during the period. State of Wyoming lifted its holdings in shares of DexCom by 3,522.0% during the fourth quarter. State of Wyoming now owns 1,811 shares of the medical device company's stock worth $141,000 after purchasing an additional 1,761 shares during the period. Waverly Advisors LLC acquired a new stake in shares of DexCom during the fourth quarter worth about $258,000. Finally, GTS Securities LLC raised its position in DexCom by 106.5% during the fourth quarter. GTS Securities LLC now owns 3,355 shares of the medical device company's stock valued at $261,000 after acquiring an additional 54,999 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company's stock.

Analysts Set New Price Targets

DXCM has been the subject of several recent research reports. Argus initiated coverage on DexCom in a research report on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. William Blair upgraded DexCom to a "strong-buy" rating in a research report on Thursday, July 31st. Truist Financial initiated coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Morgan Stanley lifted their price target on DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Finally, Raymond James Financial lifted their price target on DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research report on Thursday, July 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Price Performance

Shares of NASDAQ:DXCM traded up $1.95 during trading on Monday, reaching $69.40. The stock had a trading volume of 7,347,252 shares, compared to its average volume of 4,096,787. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The business has a fifty day moving average price of $79.90 and a 200-day moving average price of $78.25. The stock has a market cap of $27.21 billion, a PE ratio of 48.19, a PEG ratio of 1.41 and a beta of 1.48. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business's revenue was up 15.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Mark G. Foletta sold 2,750 shares of DexCom stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $81.06, for a total value of $222,915.00. Following the sale, the director directly owned 51,121 shares of the company's stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Sadie Stern sold 1,466 shares of DexCom stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 8,315 shares of company stock valued at $689,431. Insiders own 0.32% of the company's stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.